Revolution Medicines Inc [RVMD] stock is trading at $38.89, up 5.62%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RVMD shares have gain 2.45% over the last week, with a monthly amount drifted -7.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Revolution Medicines Inc [NASDAQ: RVMD] stock has seen the most recent analyst activity on July 16, 2024, when Needham reiterated its Buy rating and also boosted its price target to $62 from $46. Previously, Barclays started tracking the stock with Overweight rating on July 12, 2024, and set its price target to $52. On July 08, 2024, Jefferies initiated with a Buy rating and assigned a price target of $63 on the stock. Needham reiterated its Buy rating and increased its price target to $46 on April 12, 2024. Raymond James upgraded its rating to a Strong Buy and raised its price target to $48 on April 10, 2024. Piper Sandler started tracking with a Overweight rating for this stock on March 11, 2024, and assigned it a price target of $43. In a note dated January 05, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $31 to $34.
Revolution Medicines Inc [RVMD] stock has fluctuated between $29.55 and $62.40 over the past year. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Revolution Medicines Inc [NASDAQ: RVMD] shares were valued at $38.89 at the most recent close of the market. An investor can expect a potential return of 77.42% based on the average RVMD price forecast.
Analyzing the RVMD fundamentals
Revolution Medicines Inc [NASDAQ:RVMD] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.30 points at the first support level, and at 35.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.95, and for the 2nd resistance point, it is at 41.02.
Ratios To Look Out For
For context, Revolution Medicines Inc’s Current Ratio is 14.20. As well, the Quick Ratio is 14.20, while the Cash Ratio is 3.31.
Transactions by insiders
Recent insider trading involved Cislini Jeff, General Counsel, that happened on Jan 21 ’25 when 2406.0 shares were sold. Officer, JEFFREY TODD CISLINI completed a deal on Jan 21 ’25 to buy 2406.0 shares. Meanwhile, Chief Operating Officer Horn Margaret A sold 4329.0 shares on Dec 16 ’24.
